| 000 | 01779 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515172013.0 | ||
| 264 | 0 | _c20091207 | |
| 008 | 200912s 0 0 eng d | ||
| 022 | _a1437-7799 | ||
| 024 | 7 |
_a10.1007/s10157-009-0196-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOkada, Tadashi | |
| 245 | 0 | 0 |
_aTolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. _h[electronic resource] |
| 260 |
_bClinical and experimental nephrology _cOct 2009 |
||
| 300 |
_a438-446 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xtoxicity |
| 650 | 0 | 4 | _aAntidiuretic Hormone Receptor Antagonists |
| 650 | 0 | 4 |
_aBenzazepines _xtherapeutic use |
| 650 | 0 | 4 |
_aDesmin _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIntracellular Signaling Peptides and Proteins _xmetabolism |
| 650 | 0 | 4 |
_aKidney Glomerulus _xcytology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMembrane Proteins _xmetabolism |
| 650 | 0 | 4 |
_aNephrosis _xchemically induced |
| 650 | 0 | 4 | _aOrgan Size |
| 650 | 0 | 4 |
_aPodocytes _xdrug effects |
| 650 | 0 | 4 |
_aPuromycin Aminonucleoside _xtoxicity |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 | _aTolvaptan |
| 650 | 0 | 4 |
_aWT1 Proteins _xmetabolism |
| 700 | 1 | _aSakaguchi, Toshifumi | |
| 700 | 1 | _aHatamura, Ikuji | |
| 700 | 1 | _aSaji, Fumie | |
| 700 | 1 | _aNegi, Shigeo | |
| 700 | 1 | _aOtani, Haruhisa | |
| 700 | 1 | _aMuragaki, Yasuteru | |
| 700 | 1 | _aKawachi, Hiroshi | |
| 700 | 1 | _aShigematsu, Takashi | |
| 773 | 0 |
_tClinical and experimental nephrology _gvol. 13 _gno. 5 _gp. 438-446 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10157-009-0196-0 _zAvailable from publisher's website |
| 999 |
_c18879153 _d18879153 |
||